Navigation Links
Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

stration trials and has the potential to be the first Hsp90 inhibitor to reach the market. Our TIME registration program for tanespimycin in patients with multiple myeloma is on track to be initiated in the third quarter of 2007, which will be a major milestone for our company."

Phase 2 Tanespimycin Melanoma Trial

Tanespimycin binds to and inhibits the activity of Hsp90. Hsp90 inhibition results in the degradation of a variety of RAF family proteins, including mutant BRAF. As the majority of melanomas have activation of the BRAF-MAP kinase pathway, it is postulated that tanespimycin interrupts the MAP kinase pathway and may lead to clinically significant anti-melanoma effects. The Phase 2 trial of tanespimycin was designed as a multi-center two-stage Simon design study; continuation to the second stage required at least 1 of the first 9 patients to have a progression-free survival (PFS) time of at least 24 weeks, the primary endpoint of the trial. Eligible patients had stage M1 melanoma, measurable/unresectable disease and had progressed within 3 months of study entry with no more than 1 prior chemotherapy treatment for metastatic melanoma. Tanespimycin was administered at a dose of 275 mg/m2 by 1-2 hour intravenous infusion 2 times per week every 2 out of 3 weeks until disease progression or toxicity. 20 patients have been enrolled, and efficacy data are available on 14 evaluable patients. One of the 6 evaluable patients with a BRAF mutation (V600E) showed evidence of anti-melanoma activity. An additional patient with BRAF mutation continues on study but is too early to assess for efficacy at present. The safety profile has been manageable and included predominantly Grade 1 and 2 toxicities (constitutional and gastrointestinal symptoms). Grade 3 or 4 toxicity, which was generally manageable and reversible, resulted in treatment discontinuation in 2 patients. Accrual is continuing toward the goal of enrolling a total of 30 evaluable patients (with cont
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:5/21/2013)... May 21, 2013  NxStage Medical, Inc. (Nasdaq: ... products, today announced that it has entered into new ... in-center products to DaVita, the kidney care division of ... ) For the use of products for ... , NxStage has executed a second amended and restated ...
(Date:5/21/2013)... New data released today at the ... that the NeuroStar TMS Therapy System ® ... in patients with Major Depressive Disorder (MDD) during ... through one year of treatment.  At the end ... symptomatic improvement while 41 percent reported complete remission. ...
(Date:5/21/2013)... Quebec , May 21, 2013 ... (NYSE: VRX ) (TSX: ... ten directors nominated at its 2013 ... detailed results of the vote for ... out below:  NameForWithheldRonald H. Farmer235,731,9341,964,748Robert A. ...
Breaking Medicine Technology:NxStage Announces New Agreements with DaVita 2New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 2New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 3New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 4Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2
... Astellas Pharma US, Inc. ("Astellas") recently hired Mark ... oncology. Reporting directly to Patrick Shea, senior vice ... responsible for all U.S. commercial activities supporting marketed ... lead commercial planning for early stage development compounds. ...
... The Targetech Innovation Center, supported by a strategic ... developing pipeline of biomedical device opportunities poised to begin ... "This is an exciting development in the strategic ... effort, we will see more companies locating to Akron. ...
Cached Medicine Technology:Astellas Announces Vice President of Sales and Marketing for U.S. Oncology Franchise 2Akron Relationship with Israeli Incubator, Targetech, Shows Promise 2Akron Relationship with Israeli Incubator, Targetech, Shows Promise 3
(Date:5/21/2013)... 2013 Phoseon Technology will present their ... 20th Annual IMI European Ink Jet Conference (June ... Phoseon continues to invest in product development to enable ... UV LED curing in printing applications. Phoseon currently ... market offering both air cooled and water cooled solutions ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Modern ... the help of Texas Counseling’s Sexuality and Relationship ... and the development of healthier habits for their ... available for both couples and individuals at Texas ... their relationships and learn skills to develop long ...
(Date:5/21/2013)... Repository (DoDSR), University of Cincinnati (UC) researchers have identified ... which could help with earlier diagnosis and intervention in ... finding, the first of its kind and led by ... presentation by staff from Walter Reed National Military Medical ... 18-21 in Orlando, Fla. , The DoDSR is ...
(Date:5/21/2013)... May 21, 2013 The Las Vegas personal ... to announce that Crawford Gates, a senior at Coronado High ... college scholarship essay contest . As the winner of the ... essay contest started on Dec. 1, 2012 and ran through ... to submit a three-page minimum essay on “The Role of ...
(Date:5/21/2013)... A new study appearing in the ... stem cells harvested from fat (adipose) are more potent ... modulate the body’s immune system. , The finding ... as adipose tissue-derived stem cells (AT-SCs) are far more ... marrow and can be collected from waste material from ...
Breaking Medicine News(10 mins):Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3
... fears associated ... with common diabetes complication, ALEXANDRIA, Va., Oct. 4 ... ghosts and,goblins. But for some, there is something that is ... is a diabetes complication for both men and women.,According to ...
... N.J., Oct. 4 The National Confectioner,s,Association has ... go trick-or-treating,this year. With this in mind, Halloween ... brushing habits to their children. "Since candy ... eating on Halloween. Kids can enjoy chocolate and,lollipops ...
... benefit management ... organizations, ST. ... pharmacy benefit management, announced today it has,achieved URAC Pharmacy Benefit Management ... encourage PBM,industry best practices, promote quality improvement and protect and,empower consumers. ...
... 3 The following is a,statement by Michael Bender, ... credit, the US Food and Drug Administration and its ... a considerable,number of years to present a balanced and ... They recognized that there is,there is enough mercury in ...
... 3 EpiCept Corporation,(Nasdaq and OMX Nordic Exchange: ... will be presenting at the 2007 BIO InvestorForum ... at the Palace Hotel in San,Francisco, California. Mr. ... http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO ) The presentation will ...
... be allergic to,work? If you experience symptoms of allergies ... asthma. This disorder is defined as,reversible airflow obstruction caused ... harmful substances while "on the,job," according to the American ... that about 15%, or 1 in 7, of adult ...
Cached Medicine News:Health News:Diabetes in the Bedroom: Scarier than Halloween? 2Health News:Parents can Help Young Superheroes Battle Cavities on Halloween Night 2Health News:Prime Therapeutics Announces URAC Accreditation 2Health News:New Fish Advice Throws Baby Out With the Bath Water, Says Mercury Watchdog Group 2Health News:EpiCept Corporation to Present at the 2007 BIO InvestorForum 2Health News:EpiCept Corporation to Present at the 2007 BIO InvestorForum 3Health News:AAAAI: Asthma on the Job 2Health News:AAAAI: Asthma on the Job 3
MT-BT-5011-25 Prostate seeding needle (set of 25 unloaded needles).,MT-BT-5011-P Prostate seeding needle, pre-plugged and pre-sterilized, unloaded or for use with MEDTECs ASAP™ pre-load seedin...
... offers five classes of resectoscope electrodes ... loops, knife, roller bar & ball, ... only electrodes specifically integrated into the ... removal with minimal bleeding, increased visibility, ...
... and MRO™-2005 Rigid Percutaneous Nephroscopes combine ... throughput capacity with proven MRO performance. ... with small size sheaths. The MRO™-20 ... easy positioning during percutaneous procedures. The ...
... Resectoscope is based on the award winning ... the surgeon to perform TURis - resection ... element, HF cable and electrodes, Olympus OES ... in saline, supporting both, standard TUR and ...
Medicine Products: